


Enantioselective One-Pot Conjugate Addition of Grignard Reagents to Cyclic Enones Followed by Amidomethylation

Filip Bilčík,[†] Michal Drusan,[†] Jozef Marák,[‡] and Radovan Šebesta^{*,†}

[†]Department of Organic Chemistry and [‡]Department of Analytical Chemistry, Faculty of Natural Sciences, Comenius University, Mlynska dolina CH-2, SK-84215 Bratislava, Slovakia

Supporting Information

ABSTRACT: Enantioselective conjugate addition of Grignard reagents to enones, catalyzed by Cu-Taniaphos or Josiphos complex, affords chiral enolates. Ensuing one-pot Mannich reaction with TiCl₄-generated imine leads to aminocarbonyl compounds with benzyl-oxycarbonyl-protected nitrogen. Both diastereomers of these compounds are isolated in moderate yields but high enantiomeric purities (up to er 97.5:2.5).



There is a growing demand for synthesis of compounds with multiple stereogenic centers and functional groups. However, efficient and stereocontrolled construction of complex molecules is still a considerable challenge. Stepwise processes, in which each reaction step is followed by a purification operation, are slow and laborious. Therefore, stereoselective domino reactions or one-pot arrangements of reactions constitute a significant improvement in terms of step economy.¹ Performing such transformations in a catalytic manner adds to the benefits. Domino reactions require appropriate initiator reaction which provides a reactive intermediate for the subsequent step. A convenient starting reaction is a metal-catalyzed conjugate addition of organometallic reagents to α,β -unsaturated carbonyl compounds.^{2–10} The 1,4-addition of organometallic nucleophiles affords reactive metal enolates, which can be advantageously reacted with a broad range of electrophilic reagents.^{11,12} Such enolate trapping reactions work well with aldehydes,^{13–17} alkyl halides,^{18,19} allylic bromides and acetates,^{20–23} nitroso compounds,²⁴ metal enolates also open epoxides,²⁵ take part in cross-coupling,²⁶ or cyclopropanation reactions.²⁷ The concept was also utilized in an intramolecular fashion with another unsaturated carbonyl compound.^{28–30} Imines also acted as electrophilic trapping reagents for zinc enolates formed by conjugate addition of dialkylzinc reagents.^{31–33} Zinc enolates are most commonly used because of their easy formation and appropriate reactivity. However, structural variability is difficult to obtain because of limited availability of dialkylzinc reagents. On the other hand, magnesium enolates can be formed by conjugate addition with a broad range of Grignard reagents. Nevertheless, magnesium enolates were used in trapping reactions to much lesser extent.^{16,34,35} We have showed that Mg enolates resulting from Cu-catalyzed addition of Grignard reagents can be trapped with imines derived from aromatic aldehydes.^{36,37} Although seemingly simple, enolate trapping with formaldehyde-derived imines is unknown, because of instability of such imines. Such methodology, however, would broaden the scope of enolate trapping by opening a way to new β -aminocarbonyl compounds in a catalytic manner. We were inspired by the

work of Evans³⁸ and Seebach^{39,40} on diastereoselective synthesis of β -amino acids. In this methodology, a titanium enolate, usually obtained by a soft enolization of an acyl oxazolidone, reacted with formaldehyde imine equivalent, formed in situ from CbzNHCH₂OR by the action of TiCl₄. In this context, we asked whether amidomethylation can be performed also with enolates formed by enantioselective conjugate addition. This report shows the results using cyclic and linear enones with several Grignard reagents.


Conjugate additions of Grignard reagents to cyclic enones,^{41–44} and our own studies³⁶ of enolate trapping with imines, served as a starting point for our investigation. The conjugate addition of ethylmagnesium bromide was catalyzed by a complex formed in situ from CuCl and ferrocene ligand Taniaphos in an ethereal solvent. Imine was generated by treating amidomethylation reagent with TiCl₄ in a separate flask. We quickly discovered that the projected enolate trapping with formaldehyde imine equivalent would not be compatible with oxygenated solvents, such as Et₂O or *t*-BuOMe, because of high oxophilicity of titanium. It is, however, possible to perform the conjugate addition in ethereal solvents such as *t*-BuOMe or Et₂O and then add a solution of amidomethylation reagent with TiCl₄ in CH₂Cl₂. In this way, the reaction of cyclohex-2-enone (**1**) with EtMgBr catalyzed by Cu-Taniaphos complex afforded Cbz-protected aminocarbonyl compound **2** (Scheme 1).

The conjugate addition of organometallic reagents can be performed also in CH₂Cl₂ at low temperatures.⁴⁵ Therefore, we also tried conjugate addition of EtMgBr followed by amidomethylation in CH₂Cl₂. This reaction set up led to the best outcome of the enolate trapping. By this way, compound **2** was isolated in overall 64% yield (sum of isolated *trans*- and *cis*-**2**). Product **2** always formed as a mixture of *trans*- and *cis*-diastereomers. It was, however, surprising that diastereoselectivity was relatively low with typical ratio *trans/cis* 2:1. On the

Received: October 20, 2011

Published: November 27, 2011

Scheme 1



other hand, both diastereoisomers can be separated by column chromatography. Enantiomeric purity of both *trans*- and *cis*-**2** was high (up to e.r. of 97:3). The most reliable results were obtained with CuCl as copper source. Table 1 summarizes the results of screening for optimal solvent and copper source.


Table 1. Screening for Conditions for the One-Pot Reaction of Ketone **1** with EtMgBr^a

CuX	solvent	yield (%) (<i>trans/cis</i>)	dr ^b	er (<i>trans/cis</i>) ^c
CuCl	<i>t</i> -BuOMe	28/20	2.4:1	96:4/95:5
CuCl	Et ₂ O	28/16	2:1	93:7/88:12
CuCl ^d	CH ₂ Cl ₂	37/21	2.1:1	96:4/95:5
CuCl ^e	CH ₂ Cl ₂	41/23	1.6:1	96.5:3.5/97:3
CuCl	<i>m</i> THF ^f	32/2	2.3:1	79:21/60:40
CuCl	THF	21/23	3.2:1	52:48/60:40 (-)
CuBr.SMe ₂	CH ₂ Cl ₂	36/18	2.5:1	95:5/92:8
CuTC	CH ₂ Cl ₂	34/16	2.3:1	95:5/84:16
Cu(OTf) ₂	CH ₂ Cl ₂	22/15	2.3:1	92:8/88:12
[Cu(MeCN) ₄] PF ₆	CH ₂ Cl ₂	32/19	2:1	86:14/92:8
CuI	CH ₂ Cl ₂	23/17	2.2:1	94:6/91:9
CuF ₂	CH ₂ Cl ₂	20/12	2.3:1	53.5:46.5/52:48

^aAll reactions were carried out with 375 μmol of cyclohex-2-enone, 563 μmol of MeMgBr, 18.8 μmol of CuX (5 mol %), and 22.5 μmol of Taniaphos (6 mol %) in 3.75 mL of solvent. ^bDetermined by ¹H NMR of the crude reaction mixture. ^cDetermined by HPLC. ^dAverage of two parallel runs. ^eCatalyst loading 10 mol %. ^f*m*THF stands for 2-methyltetrahydrofuran.

With proper experimental conditions, we tested a variety of alkyl Grignard reagents in the reaction with cyclohex-2-enone (**1**) (Scheme 2). Compounds **3–7** were also obtained as

Scheme 2



separable *trans*- and *cis*-isomers, with similarly modest diastereomeric ratios, typically 2:1. Enantiomeric ratios were usually high (up to er of 97.5:2.5) with the exception of

cyclopentylmagnesium bromide, which afforded compound **6** in moderate enantiomeric purity (er 87:13). Arylmagnesium halides were not used in the one-pot reaction because they are unreactive in the conjugate addition catalyzed by Cu–Taniaphos complex.^{36,41} We also verified conjugate addition with methylmagnesium bromide in CH₂Cl₂ without subsequent amidomethylation. GC analysis of the reaction mixture showed 98% conversion and 77% of the 1,4-addition product. Table 2

Table 2. One-Pot Reaction of Enone **1** with Various Grignard Reagents^a

RMgX	yield (%) (<i>trans/cis</i>)	dr ^b	er (<i>trans/cis</i>) ^c
MeMgBr	47/19	2:1	96:4/97.5:2.5
MeMgI	20/7	2.7:1	92:8/94:6
EtMgBr	37/21	2.1:1	96:4/95:5
<i>n</i> -PentMgBr	33/30	2.4:1	96:4/80:20
<i>i</i> -PentMgBr	21/13	2.2:1	96:4/80:20
CpMgBr	10/6	n.d.	87:13/87:13
HexMgBr	26/15	1.8:1	96:4/96:4

^aAll reaction were carried out with 375 μmol of enone, 563 μmol of RMgBr, 18.8 μmol of CuCl (5 mol %), and 22.5 μmol of Taniaphos (6 mol %) in 3.75 mL of CH₂Cl₂. ^bDetermined by ¹H NMR of the crude reaction mixture. ^cDetermined by HPLC.

summarizes the results of the one-pot reaction of enone **1** with several Grignard reagents.

The scope of the reaction with respect to enone was evaluated on several cyclic α,β-unsaturated ketones. 4,4-Dimethylcyclohex-2-enone afforded expected product **8** of the one-pot reaction with MeMgBr. Yields and enantioselectivities were slightly lower, probably because of higher steric crowding near C-3 atom (Figure 1). This notion is also supported by the fact





Figure 1. Products of one-pot reactions with other cyclic enones.

that, the reaction with EtMgBr and HexMgBr did not proceed with chiral Cu–Taniaphos catalyst. Corresponding products **9** and **10** were only isolated from racemic reactions carried out with a stoichiometric amount of copper and PBU₃ as ligand. Using cyclopent-2-enone as substrate, we isolated only traces of the desired product. All additions to 4,4-dimethylcyclohex-2-enone were accompanied by a significant amount of 1,2-addition product, which is inactive in amidomethylation reaction. On the other hand, with cyclohept-2-enone, a one-pot reaction product **11** was isolated in 20% yield and with an er of 87:13 (*trans*). In this case, however, we were not able to isolate diastereoisomers (Figure 1).

Relative configuration of both diastereoisomers of compound **9** was determined by 2D NMR techniques. Assignment of signals was performed from gDQCOSY and gHSQCAD experiments, and then the spatial relationship of relevant protons was deduced from NOESY experiments. All other compounds were assigned by comparison of H–H coupling constants between COCH and CHNH. For *trans*-isomers $J_{\text{HH}} = 6.5–6.9$ Hz and for *cis*-isomers $J_{\text{HH}} = 9.0–10.0$ Hz.

We also tested the one-pot reaction on linear enones (Scheme 3). In contrast to the one-pot reaction with cyclic enones,

Scheme 3



conjugate addition on linear enones performed in CH₂Cl₂ was less enantioselective. Therefore, we performed the reaction of oct-2-enone (**10**) with methyl-, ethyl-, and hexylmagnesium bromide in *t*-BuOMe, and only amidomethylating reagent was added in CH₂Cl₂. In this case, we used Josiphos ligand because it works well in the conjugate addition of Grignard reagents to linear enones.⁴⁶ Products **13**–**15** were isolated in slightly lower yields and as diastereomeric mixtures. Enantioselectivities were, however, high, up to 97.5:2.5.

The one-pot conjugate addition and amidomethylation, both on cyclic and linear enones, affords products with diastereoselectivity lower than expected. We proposed that it can be the result of TiCl₄-mediated epimerization of the product. Control experiments proved this conjecture. Stirring pure diastereomers, either (*R,R*)-**2** or (*R,S*)-**2**, in the presence of TiCl₄ at -60 °C lead in both cases to diastereomeric mixtures *trans/cis* 2:1. Attempts at thermodynamic equilibration either in acidic (*p*TsOH in refluxing toluene) or basic (DBU in CH₂Cl₂) conditions also afforded similar results.

We have also investigated the nature of amidomethylating reagent by ¹H NMR. Addition of TiCl₄ led to downfield shift of protons indicating only complexation of titanium to oxygen. The corresponding imine was not detected.

In summary, we report here a catalytic one-pot conjugate addition followed by amidomethylation. Magnesium enolates, formed by enantioselective copper-catalyzed conjugate addition of Grignard reagents to enones, can be trapped with TiCl₄-generated imine. In this way, Cbz-protected aminocarbonyl compounds were prepared in moderate yields. Diastereoselectivities were relatively low because of Ti-mediated epimerization of the products, but diastereomers (from cyclic enones) were separated by column chromatography. Enantiomeric purities of obtained compounds were high (up to e.r. 97.5:2.5) in the majority of examples.

EXPERIMENTAL SECTION

General Considerations. All reactions were carried out under nitrogen using standard Schlenk techniques. Commercially available reagents were used without further purification. Solvents were dried according to the standard procedures.

General Procedure for One-Pot Reaction on Cyclic Ketones. Ligand Taniaphos (15.5 mg, 22.5 μmol) and CuCl (1.9 mg, 18.8 μmol) were dissolved in CH₂Cl₂ (3.75 mL), and the resulting solution was stirred 1 h at rt. The reaction mixture was then cooled at -60 °C, and ketone (375 μmol) was added via syringe. The resulting mixture was stirred for an additional 10 min at -60 °C. Into this mixture, Grignard reagent (563 μmol) was added during 5 min and the mixture was stirred for 2 h at -60 °C. In another flask, TiCl₄ (35 μL, 330 μmol) was added into a solution of CbzNHCH₂O-*i*-Pr (300 μmol)

dissolved in CH₂Cl₂ (2.5 mL) at -40 °C. This solution was stirred for 2 h at -40 °C, and then it was added via canula to the solution of conjugate addition at -60 °C. The temperature of the resulting mixture was allowed to rise to rt overnight. The reaction was quenched with aq NH₄Cl and then extracted with CH₂Cl₂. Combined organic extracts were concentrated. Column chromatography (SiO₂, hexane/EtOAc/CH₂Cl₂ 83:14:3) of the crude product afforded pure diastereomers of the product. The nantiomeric ratio was determined by HPLC with chiral stationary phase and detected by UV at 211 nm.

(*R,R*)-Benzyl ((2-Ethyl-6-oxocyclohexyl)methyl)carbamate ((*R,R*)-2**).** Following general procedure for cyclic ketones with EtMgBr: colorless oil; [α]_D -8.2 (c 1.0, CHCl₃, 92% ee); ¹H NMR (300 MHz, CDCl₃, δ) 7.40–7.27 (m, 5H), 5.39 (br, 1H), 5.15–4.98 (m, 2H), 3.55 (ddd, *J* = 13.8, 6.7, 2.6 Hz, 1H), 3.28 (ddd, *J* = 13.9, 7.5, 6.4 Hz, 1H), 2.46–2.20 (m, 3H), 2.14–1.98 (m, 1H), 1.98–1.84 (m, 1H), 1.80–1.32 (m, 5H), 0.94 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃, δ) 213.8 (CO), 156.4 (qC), 136.7 (qC), 128.5 (CH), 128.00 (CH), 127.98 (CH), 66.5 (CH₂), 55.2 (CH), 42.3 (CH), 42.0 (CH₂), 37.8 (CH₂), 29.7 (CH₂), 25.95 (CH₂), 25.94 (CH₂), 10.0 (CH₃); HRMS (*m/z*) [M + H]⁺ calcd for C₁₇H₂₄NO₃ 290.1751, found 290.1725; HPLC (OD-H, hexane/*i*-PrOH = 85:15, 0.6 mL min⁻¹) *t*_R(major) 13.6 min, *t*_R(minor) 17.7 min; IR (ATR) ν_{max} (cm⁻¹) 3455, 3390 (m, N–H), 1699 (s, C=O).

(*S,R*)-Benzyl ((2-Ethyl-6-oxocyclohexyl)methyl)carbamate ((*S,R*)-2**).** Following the general procedure for cyclic ketones with EtMgBr: colorless oil; [α]_D +2.8 (c 1.0, CHCl₃, 92% ee); ¹H NMR (600 MHz, CDCl₃, δ) 7.39–7.27 (m, 5H), 5.12 (br, 1H), 5.10–5.02 (m, 2H), 3.38 (ddd, *J* = 14.2, 9.9, 4.5 Hz, 1H), 3.27 (ddd, *J* = 13.4, 8.2, 4.0 Hz, 1H), 2.78–2.70 (m, 1H), 2.41–2.33 (m, 1H), 2.31–2.22 (m, 1H), 2.17–2.09 (m, 1H), 1.94–1.71 (m, 4H), 1.36–1.26 (m, 1H), 1.09–0.98 (m, 1H), 0.85 (t, *J* = 7.4 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃, δ) 213.1 (CO), 156.4 (qC), 136.6 (qC), 128.5 (CH), 128.05 (CH), 128.02 (CH), 66.6 (CH₂), 55.4 (CH), 42.0 (CH), 41.5 (CH₂), 39.0 (CH₂), 27.0 (CH₂), 22.4 (CH₂), 20.2 (CH₂), 11.5 (CH₃); HRMS (*m/z*) [M + H]⁺ calcd for C₁₇H₂₄NO₃ 290.1751, found 290.1750; HPLC (OJ-H, hexane/*i*-PrOH = 95:5, 0.6 mL min⁻¹) *t*_R(major) 36.8 min, *t*_R(minor) 40.6 min; IR (ATR) ν_{max} (cm⁻¹) 3342 (m, N–H), 1698 (s, C=O).

(*R,R*)-Benzyl ((2-Methyl-6-oxocyclohexyl)methyl)carbamate ((*R,R*)-3**).** Following the general procedure for cyclic ketones with MeMgBr: colorless oil; [α]_D -1.5 (c 1.0, CHCl₃, 92% ee); ¹H NMR (300 MHz, CDCl₃, δ) 7.42–7.27 (m, 5H), 5.39 (br s, 1H), 5.07 (s, 2H), 3.56 (ddd, *J* = 13.7, 6.6, 2.7 Hz, 1H), 3.30 (td, *J* = 13.8, 6.9 Hz, 1H), 2.44–2.25 (m, 2H), 2.25–2.13 (m, 1H), 2.10–1.98 (m, 1H), 1.93–1.79 (m, 1H), 1.75–1.40 (m, 3H), 1.16 (d, *J* = 6.3 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃, δ) 213.4 (CO), 156.4 (qC), 136.7 (qC), 128.5 (CH), 128.01 (CH), 127.99 (CH), 66.5 (CH₂), 57.6 (CH), 41.9 (CH₂), 37.9 (CH₂), 36.7 (CH), 34.1 (CH₂), 26.1 (CH₂), 20.5 (CH₃); HRMS (*m/z*) [M + H]⁺ calcd for C₁₆H₂₂NO₃ 276.1594, found 276.1622; HPLC (OD-H, hexane/*i*-PrOH 85:15; 0.7 mL.min⁻¹) *t*_R(major) 14.0 min, *t*_R(minor) 17.1 min; IR (ATR) ν_{max} (cm⁻¹) 3454, 3373 (m, NH), 1699 (s, C=O).

(*S,R*)-Benzyl ((2-Methyl-6-oxocyclohexyl)methyl)carbamate ((*S,R*)-3**).** Following the general procedure for cyclic ketones with MeMgBr: colorless crystalline solid; [α]_D +4.6 (c 0.9, CHCl₃, 92% ee); ¹H NMR (300 MHz, CDCl₃, δ) 7.40–7.27 (m, 5H), 5.17 (br s, 1H), 5.12–5.00 (m, 2H), 3.38–3.17 (m, 2H), 2.78–2.66 (m, 1H), 2.52–2.39 (m, 1H), 2.39–2.17 (m, 2H), 2.02–1.81 (m, 3H), 1.77–1.58 (m, 1H), 0.81 (d, *J* = 7.2 Hz, 3H); ¹³C NMR (75 MHz, CDCl₃, δ) 213.2 (CO), 156.4 (qC), 136.6 (qC), 128.5 (CH), 128.1 (CH), 128.0 (CH), 66.6 (CH₂), 54.9 (CH), 41.8 (CH₂), 39.4 (CH₂), 35.1 (CH), 32.0 (CH₂), 22.5 (CH₂), 14.1 (CH₃); HPLC (OD-H, hexane/*i*-PrOH 95:5; 0.6 mL min⁻¹) *t*_R(major) 29.5 min, *t*_R(minor) 32.6 min; IR (ATR) ν_{max} (cm⁻¹) 3321 (s, NH), 1708, 1681 (s, C=O). Anal. Calcd for C₁₆H₂₁NO₃: C, 69.79; H, 7.69; N, 5.09. Found: C, 69.48; H, 7.65; N, 5.04.

(*R,R*)-Benzyl ((2-Oxo-6-pentylcyclohexyl)methyl)carbamate ((*R,R*)-4**).** Following the general procedure for cyclic ketones with *n*PentMgBr: colorless oil; [α]_D -5.6 (c 1.0, CHCl₃, 92% ee); ¹H NMR (600 MHz, CDCl₃, δ) 7.40–7.32 (m, 4H), 7.32–7.27 (m, 1H),

5.42–5.32 (m, 1H), 5.14–5.02 (m, 2H), 3.57 (ddd, $J = 13.7, 6.8, 2.6$ Hz, 1H), 3.28 (ddd, $J = 13.9, 7.6, 6.3$ Hz, 1H), 2.41–2.34 (m, 1H), 2.33–2.24 (m, 2H), 2.10–2.02 (m, 1H), 1.99–1.91 (m, 1H), 1.70–1.63 (m, 1H), 1.63–1.53 (m, 2H), 1.48–1.38 (m, 2H), 1.38–1.18 (m, 6H), 0.89 (t, $J = 7.0$ Hz, 3H); ^{13}C NMR (75 MHz, CDCl_3 , δ) 213.8 (CO), 156.4 (qC), 136.7 (qC), 128.5 (CH), 128.01 (CH), 127.98 (CH), 66.5 (CH₂), 55.8 (CH), 42.0 (CH₂), 41.3 (CH), 38.0 (CH₂), 33.4 (CH₂), 32.0 (CH₂), 30.3 (CH₂), 26.0 (CH₂), 25.7 (CH₂), 22.6 (CH₂), 14.1 (CH₃); HRMS (m/z) [$M + H$]⁺ calcd for $\text{C}_{20}\text{H}_{30}\text{NO}_3$ 332.2220, found 332.2230; HPLC (OD-H, hexane/*i*-PrOH = 85:15, 0.6 mL min⁻¹) t_{R} (major) 11.4 min, t_{R} (minor) 17.0 min; IR (ATR) ν_{max} (cm⁻¹) 3457 (m, N–H), 1722, 1704 (s, C=O).

(*S,R*)-Benzyl ((2-Oxo-6-pentylcyclohexyl)methyl)carbamate ((*S,R*)-4). Following the general procedure for cyclic ketones with *n*PentMgBr: colorless oil; $[\alpha]_{\text{D}} -5.5$ (c 1.0, CHCl_3 , 60% ee); ^1H NMR (600 MHz, CDCl_3 , δ) 7.42–7.28 (m, 5H), 5.19–5.00 (m, 3H), 3.38 (ddd, $J = 14.1, 10.0, 4.4$ Hz, 1H), 3.30–3.23 (m, 1H), 2.77–2.68 (m, 1H), 2.41–2.32 (m, 1H), 2.32–2.17 (m, 2H), 1.93–1.70 (m, 4H), 1.36–0.97 (m, 8H), 0.87 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR (75 MHz, CDCl_3 , δ) 213.2 (CO), 156.4 (qC), 136.6 (qC), 128.5 (CH), 128.06 (CH), 128.03 (CH), 66.6 (CH₂), 55.4 (CH), 41.5 (CH₂), 40.3 (CH), 39.1 (CH₂), 31.7 (CH₂), 27.6 (CH₂), 27.2 (CH₂), 26.6 (CH₂), 22.54 (CH₂), 22.51 (CH₂), 14.0 (CH₃); HRMS (m/z) [$M + H$]⁺ calcd for $\text{C}_{20}\text{H}_{30}\text{NO}_3$ 332.2220, found 332.2262; HPLC (OD-H, hexane/*i*-PrOH = 95:5, 0.7 mL min⁻¹) t_{R} (major) 20.4 min, t_{R} (minor) 23.2 min; IR (ATR) ν_{max} (cm⁻¹) 3387, 3328 (s, N–H), 1715, 1690 (s, C=O).

(*S,S*)-Benzyl 6-(3-Methylbutyl)-2-oxocyclohexylmethylcarbamate ((*S,S*)-5). Following the general procedure for cyclic ketones with *i*-PentMgBr: colorless oil; $[\alpha]_{\text{D}} -6.7$ (c 1.0, CHCl_3 , 60% ee); ^1H NMR (600 MHz, CDCl_3 , δ) 7.39–7.27 (m, 5H), 5.17–5.03 (m, 3H), 3.39 (ddd, $J = 14.2, 10.0, 4.5$ Hz, 1H), 3.31–3.23 (m, 1H), 2.76–2.69 (m, 1H), 2.41–2.34 (m, 1H), 2.31–2.22 (m, 1H), 2.22–2.14 (m, 1H), 1.91–1.71 (m, 4H), 1.52–1.40 (m, 1H), 1.27–1.09 (m, 2H), 1.09–0.96 (m, 2H), 0.86 (d, $J = 6.6$ Hz, 3H), 0.83 (d, $J = 6.6$ Hz, 3H, CH₃); ^{13}C NMR (75 MHz, CDCl_3 , δ) 213.2 (CO), 156.4 (qC), 136.5 (qC), 128.5 (CH), 128.04 (CH), 128.01 (CH), 66.6 (CH₂), 55.4 (CH), 41.5 (CH₂), 40.6 (CH), 39.1 (CH₂), 36.2 (CH₂), 28.0 (CH), 27.6 (CH₂), 24.9 (CH₂), 22.9 (CH₃), 22.4 (CH₂), 22.2 (CH₃); HRMS (m/z) [$M + H$]⁺ calcd for $\text{C}_{20}\text{H}_{30}\text{NO}_3$ 332.2220, found 332.2212; HPLC (OJ-H, hexane/*i*-PrOH = 92:8, 0.7 mL min⁻¹) t_{R} (minor) 12.6 min, t_{R} (major) 14.9 min; IR (ATR) ν_{max} (cm⁻¹) 3345 (m, N–H), 1704 (s, C=O).

(*R,S*)-Benzyl 6-(3-Methylbutyl)-2-oxocyclohexylmethylcarbamate ((*R,S*)-5). Following the general procedure for cyclic ketones with *i*-PentMgBr: colorless oil; $[\alpha]_{\text{D}} -6.7$ (c 1.0, CHCl_3 , 92% ee); ^1H NMR (600 MHz, CDCl_3 , δ) 7.38–7.32 (m, 4H), 7.32–7.27 (m, 1H), 5.40–5.33 (m, 1H, NH), 5.14–5.01 (m, 2H, CH₂O), 3.57 (ddd, $J = 13.7, 6.8, 2.7$ Hz, 1H), 3.28 (ddd, $J = 13.8, 7.6, 6.3$ Hz, 1H), 2.41–2.35 (m, 1H), 2.34–2.24 (m, 2H), 2.10–2.02 (m, 1H), 1.98–1.90 (m, 1H), 1.70–1.63 (m, 1H), 1.63–1.48 (m, 3H), 1.48–1.39 (m, 1H), 1.39–1.30 (m, 1H), 1.30–1.21 (m, 1H), 1.18–1.09 (m, 1H), 0.94–0.84 (m, 6H); ^{13}C NMR (75 MHz, CDCl_3 , δ) 213.8 (CO), 156.4 (qC), 136.7 (qC), 128.5 (CH), 128.00 (CH), 127.97 (CH), 66.5 (CH₂), 55.7 (CH), 42.0 (CH₂), 41.5 (CH), 38.0 (CH₂), 35.1 (CH₂), 31.1 (CH₂), 30.3 (CH₂), 28.2 (CH), 26.0 (CH₂), 23.0 (CH₃), 22.3 (CH₃); HRMS (m/z) [$M + H$]⁺ calcd for $\text{C}_{20}\text{H}_{30}\text{NO}_3$ 332.2220, found 332.2220; HPLC (OD-H, hexane/*i*-PrOH = 85:15, 0.6 mL min⁻¹) t_{R} (major) 11.2 min, t_{R} (minor) 16.6 min; IR (ATR) ν_{max} (cm⁻¹) 3455, 3390 (m, N–H), 1703 (s, C=O).

(*S,S*)-Benzyl ((6-Cyclopentyl-2-oxocyclohexyl)methyl)carbamate ((*S,S*)-6). Following the general procedure for cyclic ketones with CpMgBr: colorless crystalline solid; ^1H NMR (300 MHz, CDCl_3 , δ) 7.40–7.27 (m, 5H), 5.06 (s, 2H), 4.84 (brs, 1H), 3.67–3.48 (m, 1H), 3.40 (td, $J = 13.4, 5.1$ Hz, 1H), 2.75–2.61 (m, 1H), 2.61–2.45 (m, 1H), 2.35–2.19 (m, 1H), 2.10–1.91 (m, 1H), 1.91–1.40 (m, 11H), 1.15–0.96 (m, 2H); ^{13}C NMR (75 MHz, CDCl_3 , δ) 213.7 (CO), 156.3 (qC), 136.4 (qC), 128.5 (CH), 128.1 (CH), 128.0 (CH), 66.8 (CH₂), 55.4 (CH), 47.3 (CH), 41.6 (CH), 39.2 (CH₂), 38.8 (CH₂), 32.1 (CH₂), 30.9 (CH₂), 27.1 (CH₂), 25.03 (CH₂), 24.98 (CH₂), 24.7 (CH₂); HPLC (OD-H, hexane/*i*-PrOH = 95:5, 0.6 mL min⁻¹)

t_{R} (major) 29.9 min, t_{R} (minor) 33.2 min; IR (ATR) ν_{max} (cm⁻¹) 3297 (m, N–H), 1723, 1694 (s, C=O). Anal. Calcd for $\text{C}_{20}\text{H}_{27}\text{NO}_3$: C, 72.92; H, 8.26; N, 4.25. Found: C, 72.61; H, 8.27; N, 4.03.

(*R,S*)-Benzyl ((6-Cyclopentyl-2-oxocyclohexyl)methyl)carbamate ((*R,S*)-6). Following the general procedure for cyclic ketones with CpMgBr: colorless oil; $[\alpha]_{\text{D}} -0.8$ (c 0.8, CHCl_3 , 74% ee); ^1H NMR (600 MHz, CDCl_3 , δ) 7.38–7.27 (m, 5H), 5.35 (br, 1H), 5.09 (d, $J = 12.3$ Hz, 1H), 5.04 (d, $J = 12.3$ Hz, 1H), 3.59 (ddd, $J = 13.6, 6.6, 3.3$ Hz, 1H), 3.32 (ddd, $J = 14.0, 8.0, 6.3$ Hz, 1H), 2.45–2.35 (m, 2H), 2.28 (ddd, $J = 12.8, 12.6, 6.1$ Hz, 1H), 2.20–2.10 (m, 1H), 2.05 (dq, $J = 9.1, 4.6$ Hz, 1H), 1.89–1.82 (m, 1H), 1.78–1.69 (m, 2H), 1.69–1.45 (m, 7H), 1.32–1.23 (m, 2H); ^{13}C NMR (150 MHz, CDCl_3 , δ) 214.0 (CO), 156.4 (qC), 136.6 (qC), 128.4 (CH), 127.98 (CH), 127.94 (CH), 66.5 (CH₂), 55.4 (CH), 44.2 (CH), 41.5 (CH₂), 40.5 (CH), 38.6 (CH₂), 30.3 (CH₂), 26.2 (CH₂), 25.7 (CH₂), 25.5 (CH₂), 25.3 (CH₂), 24.6 (CH₂); HRMS (m/z) [$M + H$]⁺ calcd for $\text{C}_{20}\text{H}_{28}\text{NO}_3$ 330.2064, found 330.2030; HPLC (OD-H, hexane/*i*-PrOH = 85:15, 0.6 mL min⁻¹) t_{R} (major) 13.9 min, t_{R} (minor) 17.9 min; IR (ATR) ν_{max} (cm⁻¹) 3335 (m, N–H), 1705 (s, C=O).

(*R,R*)-Benzyl ((6-Hexyl-2-oxocyclohexyl)methyl)carbamate ((*R,R*)-7). Following the general procedure for cyclic ketones with HexMgBr: colorless oil; $[\alpha]_{\text{D}} -8.4$ (c 1.0, CHCl_3 , 92% ee); ^1H NMR (300 MHz, CDCl_3 , δ) 7.42–7.27 (m, 5H), 5.43–5.30 (m, 1H), 5.15–5.01 (m, 2H), 3.57 (ddd, $J = 13.8, 6.9, 2.8$ Hz, 1H), 3.27 (ddd, $J = 13.9, 7.7, 6.2$ Hz, 1H), 2.44–2.20 (m, 3H), 2.13–2.01 (m, 1H), 2.01–1.88 (m, 1H), 1.75–1.10 (m, 13H), 0.88 (t, $J = 6.2$ Hz, 3H); ^{13}C NMR (150 MHz, CDCl_3 , δ) 213.9 (CO), 156.4 (qC), 136.7 (qC), 128.5 (CH), 128.01 (CH), 127.98 (CH), 66.5 (CH₂), 55.8 (CH), 42.0 (CH₂), 41.4 (CH), 38.0 (CH₂), 33.5 (CH₂), 31.8 (CH₂), 30.3 (CH₂), 29.5 (CH₂), 26.04 (CH₂), 26.01 (CH₂), 22.65 (CH₂), 14.1 (CH₃); HRMS (m/z) [$M + H$]⁺ calcd for $\text{C}_{21}\text{H}_{32}\text{NO}_3$ 346.2377, found 346.2390; HPLC (OD-H, hexane/*i*-PrOH = 85:15, 0.6 mL min⁻¹) t_{R} (major) 11.0 min, t_{R} (minor) 15.6 min; IR (ATR) ν_{max} (cm⁻¹) 3455, 3379 (m, N–H), 1703 (s, C=O).

(*S,R*)-Benzyl ((6-Hhexyl-2-oxocyclohexyl)methyl)carbamate ((*S,R*)-7). Following the general procedure for cyclic ketones with HexMgBr: colorless oil; $[\alpha]_{\text{D}} -9.3$ (c 1.2, CHCl_3 , 92% ee); ^1H NMR (300 MHz, CDCl_3 , δ) 7.42–7.27 (m, 5H), 5.20–5.00 (m, 3H), 3.32 (dddd, $J = 21.9, 13.6, 9.0, 4.3$ Hz, 2H), 2.79–2.65 (m, 1H), 2.45–2.15 (m, 3H), 1.97–1.65 (m, 4H), 1.40–0.96 (m, 10H), 0.87 (t, $J = 6.7$ Hz, 3H); ^{13}C NMR (150 MHz, CDCl_3 , δ) 213.2 (CO), 156.4 (qC), 136.6 (qC), 128.5 (CH), 128.06 (CH), 128.03 (CH), 66.6 (CH₂), 55.4 (CH), 41.5 (CH₂), 40.3 (CH), 39.1 (CH₂), 31.8 (CH₂), 29.2 (CH₂), 27.7 (CH₂), 27.2 (CH₂), 26.9 (CH₂), 22.6 (CH₂), 22.5 (CH₂), 14.1 (CH₃); HRMS (m/z) [$M + H$]⁺ calcd for $\text{C}_{21}\text{H}_{32}\text{NO}_3$ 346.2377, found 346.2394; HPLC (OD-H, hexane/*i*-PrOH = 85:15, 0.6 mL min⁻¹) t_{R} (major) 20.8 min, t_{R} (minor) 23.4 min; IR (ATR) ν_{max} (cm⁻¹) 3347 (m, N–H), 1704 (s, C=O).

(*S,S*)-Benzyl ((2-Methyl-3,3-dimethyl-6-oxocyclohexyl)methyl)carbamate ((*S,S*)-8). Following the general procedure for cyclic ketones with MeMgBr: colorless crystalline solid; mp 73–78 °C (heptane); ^1H NMR (600 MHz, CDCl_3 , δ) 7.39–7.32 (m, 4H), 7.32–7.28 (m, 1H), 5.18 (br, 1H), 5.10 (d, $J = 12.2$ Hz, 1H), 5.05 (d, $J = 12.2$ Hz, 1H), 3.33 (ddd, $J = 13.3, 9.4, 3.8$ Hz, 1H), 3.25–3.17 (m, 1H), 2.99–2.93 (m, 1H), 2.41 (dt, $J = 14.1, 7.0$ Hz, 1H), 2.21 (ddd, $J = 14.5, 5.0, 1.7$ Hz, 1H), 1.93–1.85 (m, 1H), 1.81 (dt, $J = 13.7, 5.0$ Hz, 1H), 1.55 (tdd, $J = 13.6, 7.0, 1.7$ Hz, 1H), 1.38 (s, 3H), 0.98 (s, 3H), 0.74 (d, $J = 7.1$ Hz, 3H); ^{13}C NMR (150 MHz, CDCl_3 , δ) 213.4 (qC-CO), 156.3 (qC), 136.6 (qC), 128.5 (CH-Ph), 128.04 (CH-Ph), 128.03 (CH-Ph), 66.6 (CH₂), 51.0 (CH), 45.5 (CH), 39.7 (CH₂), 38.3 (CH₂), 34.5 (CH₂), 33.7 (qC), 28.3 (CH₃), 26.8 (CH₃), 10.8 (CH₃); HRMS (m/z) [$M + H$]⁺ calcd for $\text{C}_{18}\text{H}_{26}\text{NO}_3$ 304.1907; found 304.1915. HPLC (OD-H, hexane/*i*-PrOH = 90:10, 0.6 mL min⁻¹) t_{R} (major) 29.3 min, t_{R} (minor) 33.5 min; IR (ATR) ν_{max} (cm⁻¹) 3372, 3329 (m, N–H), 1715, 1697 (s, C=O).

(*R,S*)-Benzyl ((2-Methyl-3,3-dimethyl-6-oxocyclohexyl)methyl)carbamate ((*R,S*)-8). Following the general procedure for cyclic ketones with MeMgBr: colorless oil; $[\alpha]_{\text{D}} -5.0$ (c 1.0, CHCl_3 , 62% ee); ^1H NMR (600 MHz, CDCl_3 , δ) 7.38–7.33 (m, 4H), 7.33–7.28 (m, 1H), 5.39 (br, 1H), 5.08 (s, 2H), 3.57 (ddd, $J = 13.8, 6.5, 2.6$ Hz, 1H),

3.29 (td, $J = 13.7, 6.8$ Hz, 1H), 2.48 (dt, $J = 14.2, 6.0$ Hz, 1H), 2.33–2.26 (m, 1H), 2.26 (ddd, $J = 13.9, 4.3, 2.8$ Hz, 1H), 1.74 (ddd, $J = 13.5, 5.9, 2.6$ Hz, 1H), 1.59 (dt, $J = 14.1, 4.3$ Hz, 1H), 1.49 (qd, $J = 13.2, 6.7$ Hz, 1H), 1.07–1.02 (m, 6H), 0.98 (s, 3H); ^{13}C NMR (150 MHz, CDCl_3 , δ) 213.7 (qC–CO), 156.5 (qC), 136.7 (qC), 128.5 (CH–Ph), 128.02 (CH–Ph), 128.00 (CH–Ph), 66.5 (CH_2), 52.9 (CH), 44.1 (CH), 41.5 (CH_2), 38.8 (CH_2), 38.2 (CH_2), 33.5 (qC), 29.4 (CH_3), 19.0 (CH_3), 14.2 (CH_3); HRMS (m/z) $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{18}\text{H}_{26}\text{NO}_3$ 304.1907, found 304.1921; HPLC (OD–H, hexane/*i*-PrOH = 90:10, 0.6 mL min^{-1}) t_{R} (minor) 14.1 min, t_{R} (major) 19.5 min; IR (ATR) ν_{max} (cm^{-1}) 3455, 3390 (m, N–H), 1704 (s, C=O).

(*S*,S**)-Benzyl ((2-Ethyl-3,3-dimethyl-6-oxocyclohexyl)methyl)carbamate ((*S*,S**)-9). Colorless crystalline solid: mp 85–87 °C (EtOAc/hexane); ^1H NMR (300 MHz, CDCl_3 , δ) 7.44–7.27 (m, 5H), 5.21 (br, 1H), 5.08 (m, 2H), 3.43–3.23 (m, 2H), 3.00–2.90 (m, 1H), 2.41 (dt, $J = 14.0, 6.9$ Hz, 1H), 2.22 (ddd, $J = 14.6, 5.3, 2.3$ Hz, 1H), 1.79 (dt, $J = 13.5, 5.3$ Hz, 1H), 1.62–1.47 (m, 2H), 1.40–1.17 (m, 1H), 1.28 (s, 3H), 1.10–0.92 (m, 1H), 1.01 (s, 3H), 0.90 (t, $J = 7.3$ Hz, 3H); ^{13}C NMR (75 MHz, CDCl_3 , δ) 213.6 (qC–CO), 156.4 (qC), 136.6 (qC), 128.5 (CH–Ph), 128.06 (CH–Ph), 128.05 (CH–Ph), 66.6 (CH_2), 53.2 (CH), 51.6 (CH), 39.7 (CH_2), 38.3 (CH_2), 35.7 (CH_2), 34.5 (qC), 27.5 (CH_3), 27.4 (CH_3), 19.5 (CH_2), 15.9 (CH_3); HPLC (OD–H, hexane/*i*-PrOH = 95:5, 0.7 mL min^{-1}) t_{R} 24.8 min, t_{R} 27.2 min; IR (ATR) ν_{max} (cm^{-1}) 3357 (m, N–H), 1706 (s, C=O). Anal. Calcd for $\text{C}_{19}\text{H}_{27}\text{NO}_3$: C, 71.89; H, 8.57; N, 4.41. Found: C, 72.17; H, 8.64; N, 4.44.

(*R*,S**)-Benzyl ((2-Ethyl-3,3-dimethyl-6-oxocyclohexyl)methyl)carbamate ((*R*,S**)-9). Colorless crystalline solid: mp 73–75 °C (EtOAc/hexane); ^1H NMR (300 MHz, CDCl_3 , δ) 7.40–7.27 (m, 5H), 5.48 (br, 1H), 5.07 (m, 2H), 3.62 (ddd, $J = 13.5, 8.2, 2.7$ Hz, 1H), 3.16 (ddd, $J = 13.6, 8.8, 4.8$ Hz, 1H), 2.56–2.33 (m, 2H), 2.26 (ddd, $J = 14.0, 4.5, 2.8$ Hz, 1H), 1.71 (ddd, $J = 13.5, 6.1, 2.8$ Hz, 1H), 1.66–1.33 (m, 3H), 1.18–1.06 (m, 1H), 1.07 (s, 3H), 0.99 (s, 3H), 0.97 (t, $J = 7.6$ Hz, 3H); ^{13}C NMR (75 MHz, CDCl_3 , δ) 214.1 (qC–CO), 156.4 (qC), 136.6 (qC), 128.5 (CH–Ph), 128.02 (CH–Ph), 128.01 (CH–Ph), 66.5 (CH_2), 53.0 (CH), 51.8 (CH), 41.5 (CH_2), 39.1 (CH_2), 38.6 (CH_2), 34.4 (qC), 29.2 (CH_3), 22.8 (CH_2), 20.1 (CH_3), 15.0 (CH_3); HPLC (OD–H, hexane/*i*-PrOH = 85:15, 0.6 mL min^{-1}) t_{R} 12.5 min, t_{R} 17.3 min; IR (ATR) ν_{max} (cm^{-1}) 3433 (m, N–H), 1716, 1702 (s, C=O). Anal. Calcd for $\text{C}_{19}\text{H}_{27}\text{NO}_3$: C, 71.89; H, 8.57; N, 4.41. Found: C, 72.03; H, 8.63; N, 4.37.

(*S*,S**)-Benzyl ((2-Hexyl-3,3-dimethyl-6-oxocyclohexyl)methyl)carbamate ((*S*,S**)-10). Colorless oil: ^1H NMR (600 MHz, CDCl_3 , δ) 7.38–7.32 (m, 4H), 7.32–7.27 (m, 1H), 5.23 (br, 1H), 5.10 (d, $J = 12.3$ Hz, 1H), 5.04 (d, $J = 12.3$ Hz, 1H), 3.30 (dd, $J = 13.4, 4.1$ Hz, 2H), 2.95 (td, $J = 8.5, 4.2$ Hz, 1H), 2.40 (dt, $J = 13.8, 6.9$ Hz, 1H), 2.25–2.17 (m, 1H), 1.79 (dt, $J = 13.4, 5.2$ Hz, 1H), 1.60–1.49 (m, 2H), 1.28 (s, 3H), 1.32–1.16 (m, 10H), 1.00 (s, 3H), 0.86 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR (150 MHz, CDCl_3 , δ) 213.7 (CO), 156.3 (qC), 136.6 (qC), 128.5 (CH), 128.03 (CH), 66.6 (CH_2), 51.5 (CH), 51.3 (CH), 39.7 (CH₂), 38.4 (CH₂), 35.6 (CH₂), 34.5 (qC), 31.58 (CH₂), 31.55 (CH₂), 29.6 (CH₂), 27.6 (CH₃), 27.2 (CH₃), 26.8 (CH₂), 26.2 (CH₂), 14.0 (CH₃); HRMS (m/z) $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{23}\text{H}_{36}\text{NO}_3$ 374.2695, found 374.2708; HPLC (OJ–H, hexane/*i*-PrOH = 90:10, 0.7 mL min^{-1}) t_{R} 9.1 min, t_{R} 12.0 min; IR (ATR) ν_{max} (cm^{-1}) 3454, 3348 (m, N–H), 1704 (s, C=O).

(*R*,S**)-Benzyl ((2-Hexyl-3,3-dimethyl-6-oxocyclohexyl)methyl)carbamate ((*R*,S**)-10). Colorless crystalline solid: ^1H NMR (300 MHz, CDCl_3 , δ) 7.43–7.27 (m, 5H), 5.47 (br, 1H), 5.20–4.95 (m, 2H), 3.70–3.48 (m, 1H), 3.13 (ddd, $J = 13.6, 9.1, 4.6$ Hz, 1H), 2.56–2.32 (m, 2H), 2.25 (ddd, $J = 14.0, 4.3, 2.8$ Hz, 1H), 1.72 (ddd, $J = 13.4, 6.0, 2.5$ Hz, 1H), 1.65–1.42 (m, 2H), 1.42–1.09 (m, 10H), 1.06 (s, 3H), 0.98 (s, 3H), 0.88 (t, $J = 6.2$ Hz, 3H); ^{13}C NMR (150 MHz, CDCl_3 , δ) 214.0 (CO), 156.3 (qC), 136.7 (qC), 128.5 (CH), 128.00 (CH), 127.97 (CH), 66.5 (CH_2), 53.5 (CH), 50.6 (CH), 41.5 (CH_2), 39.2 (CH₂), 38.6 (CH₂), 34.3 (qC), 31.7 (CH₂), 31.1 (CH₂), 30.4 (CH₂), 29.7 (CH₂), 29.2 (CH₃), 22.7 (CH₂), 19.8 (CH₃), 14.1 (CH₃); HPLC (OD–H, hexane/*i*-PrOH = 85:15, 0.6 mL min^{-1}) t_{R} 9.6 min, t_{R} 14.6 min; IR (ATR) ν_{max} (cm^{-1}) 3458, 3327 (m, N–H), 1702 (s, C=O).

Anal. Calcd for $\text{C}_{23}\text{H}_{36}\text{NO}_3$: C, 73.96; H, 9.44; N, 3.75. Found: C, 74.19; H, 9.45; N, 3.61.

Benzyl ((2-Ethyl-7-oxocycloheptyl)methyl)carbamate (11). Following the general procedure for cyclic ketones with MeMgBr: colorless oil, diastereomeric mixture; ^1H NMR (600 MHz, CDCl_3 , δ) signals for minor diastereomer are in italics: 7.39–7.27 (m, 5H), 5.19; 5.18 (br, 1H), 5.11–5.02 (m, 2H), 3.45 (ddd, $J = 13.6, 6.8, 3.4$ Hz, 1H), 3.39–3.34 (m, 1H), 3.34–3.27 (m, 1H), 3.12–3.04 (m, 1H), 2.68–2.59 (m, 1H), 2.55–2.48 (m, 1H), 2.48–2.32 (m, 2H), 2.31–2.22 (m, 1H), 2.00–1.93 (m, 1H), 1.86–1.20 (m, 8H), 1.06–0.97 (m, 1H), 0.94 (t, $J = 7.4$ Hz, 3H), 0.85 (t, $J = 7.3$ Hz, 3H); ^{13}C NMR (150 MHz, CDCl_3 , δ) signals for minor diastereomer are in italics: 215.3; 214.9 (qC–CO), 156.42; 156.41 (qC), 136.59; 136.56 (qC), 128.5 (CH–Ph), 128.05; 128.03 (CH–Ph), 128.00 (CH–Ph), 66.59; 66.58 (CH₂), 56.8; 56.1 (CH), 43.9; 42.5 (CH₂), 41.1; 40.8 (CH₂), 39.3; 38.8 (CH), 32.4; 29.74 (CH₂), 26.4 (CH₂), 24.8; 24.3 (CH₂), 23.73; 23.66 (CH₂), 21.0 (CH₂), 12.4; 11.4 (CH₃); HRMS (m/z) $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{18}\text{H}_{26}\text{NO}_3$ 304.1907, found 304.1881; HPLC (OJ–H, hexane/*i*-PrOH = 92:8, 0.7 mL min^{-1}) t_{R} (major-trans) 16.7 min, t_{R} (minor-trans) 18.0 min, t_{R} (cis – both enantiomers) 19.3 min; IR (ATR) ν_{max} (cm^{-1}) 3442 (m, N–H), 1694 (s, C=O).

General Procedure for One-Pot Reaction on Linear Ketones. (*R,R*)-Josiphos (19.2 mg, 0.03 mmol) and CuBr·SMe₂ (5.2 mg, 0.025 mmol) were dissolved in *t*-BuOMe, and the solution was stirred for 30 min at room temperature. The solution was then cooled to –75 °C, and ketone 12 (0.5 mmol) was added. After an additional 5 min of stirring, Grignard reagent (0.5 mmol) was added during 30 min and the resulting mixture was stirred for 1.5 h at –75 °C. A mixture of CbzNHCH₂O-*i*-Pr (89.3 mg, 0.4 mmol) and TiCl₄ (55 μL , 0.48 mmol) in CH₂Cl₂ (3 mL), which was stirred in another Schlenk tube for 2 h at –60 °C was added. The reaction temperature was then allowed to reach room temperature overnight. The reaction was then quenched with a few drops of satd solution of NH₄Cl and extracted with CH₂Cl₂. Combined organic extracts were concentrated. Column chromatography (SiO₂, Hex/AcOEt 4:1–6:1) of the residue afforded pure product (mixture of diastereomers) as colorless oil. Enantiomeric and diastereomeric ratio was determined by HPLC with chiral stationary phase and detected by UV at 211 nm.

Benzyl 2-Acetyl-3-methylheptylcarbamate (13). Following the general procedure for linear ketones with MeMgBr: colorless oil, diastereomeric mixture; ^1H NMR (300 MHz, CDCl_3 , δ) 7.28–7.39 (m, 5H), 4.95–5.15 (m, 3H), 3.36–3.49 (m, 1H), 3.20–3.35 (m, 1H), 2.68–2.79 (m, 1H), 2.15 (s, 3H), 1.11–1.51 (m, 7H), 0.99, 0.81 (d, $J = 6.9$ Hz, 3H), 0.84–0.96 (m, 3H); ^{13}C NMR (75 MHz, CDCl_3 , δ): 211.8, 211.7 (CO); 156.3 (CONH); 136.5 (qC); 128.5; 128.1; 128.1 (CH); 66.6 (OCH₂); 58.2, 57.2 (CH); 38.8, 37.4 (NCH₂); 34.7, 32.9 (CH₂); 33.3; 33.1 (CH); 30.7, 29.7 (CH₃); 29.6, 29.4 (CH₂); 22.70, 22.67 (CH₂); 17.6, 15.7 (CH₃); 14.04, 14.00 (CH₃); IR (CHCl₃) ν_{max} (cm^{-1}) 3454 (w, N–H), 1705 (s, C=O), 1513 (m, σ N–H), 1241 (m, C–O); HRMS (m/z) $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{18}\text{H}_{28}\text{NO}_3$ 306.2064, found 306.2074.

Benzyl 2-Acetyl-3-ethylheptylcarbamate (14). Following the general procedure for linear ketones with EtMgBr: colorless oil; diastereomeric mixture. ^1H NMR (300 MHz, CDCl_3 , δ) 7.28–7.39 (m, 5H), 4.99–5.11 (m, 2H), 4.85 (br s, 1H), 3.34–3.47 (m, 1H), 3.16–3.29 (m, 1H), 2.72–2.89 (m, 1H), 2.15 (s, 3H), 1.65–1.79 (m, 1H), 1.09–1.51 (m, 8H), 1.01 (t, $J = 7.3$ Hz, 3H) 0.86 (t, $J = 7.1$ Hz, 3H); ^{13}C NMR (75 MHz, CDCl_3 , δ): 212.2, 212.1 (CO); 156.3 (CONH); 136.5 (C_q); 128.5 (CH_{Ph}); 128.1 (CH); 128.0 (CH); 66.6 (OCH₂); 55.4, 55.2 (CH); 40.1; 40.0 (CH); 37.6, 37.3; 30.8, 30.0; 29.72, 29.67 (CH₂); 29.53, 29.50 (CH₃); 24.6, 24.4; 22.8, 22.7 (CH₂); 14.1, 14.0 (CH₃); 12.0, 11.9 (CH₃); HRMS (m/z) $[\text{M} + \text{H}]^+$ calcd for $\text{C}_{19}\text{H}_{30}\text{NO}_3$ 320.2220, found 320.2240; IR (CHCl₃) ν_{max} (cm^{-1}) 1455 (w, N–H), 1705 (s, CO), 1513 (m, σ N–H), 1255 (w, C–O).

Benzyl 2-Acetyl-3-butylnonylcarbamate (15). Following the general procedure for linear ketones with HexMgBr: colorless oil, diastereomeric mixture; ^1H NMR (300 MHz, CDCl_3 , δ) 7.29–7.40 (m, 5H), 4.99–5.16 (m, 3H), 3.34–3.46 (m, 1H), 3.16–3.29 (m, 1H), 2.76–2.86 (m, 1H), 2.15 (s, 3H), 1.78 (m, 1H); 1.02–1.55 (m, 16H),

0.92 (t, $J = 7.3$ Hz, 3H) 0.78–0.98 (m, 3H); ^{13}C NMR (75 MHz, CDCl_3 , δ): 212.0 (CO); 156.3 (CONH); 136.5 (qC); 128.5; 128.1; 128.0 (CH); 66.6 (OCH_2); 55.6 (CH); 38.4 (CH); 31.8, 31.7; 31.6, 31.3; 30.6, 30.3; 29.7, 29.6; 29.58, 29.55 (CH_3); 29.5, 29.4; 27.5, 27.4; 24.6, 24.3; 22.9, 22.7; 22.7, 22.6; 14.10, 14.07 (CH_3); 14.0, 13.8 (CH_3); HRMS (m/z) [$\text{M} + \text{H}$] $^+$ calcd for $\text{C}_{23}\text{H}_{38}\text{NO}_3$ 376.2846, found 376.2834; IR (CHCl_3) ν_{max} (cm^{-1}) 3455 (w, N–H), 1705 (s, CO), 1513 (m, $\sigma\text{N–H}$), 1254 (w, C–O).

■ ASSOCIATED CONTENT

■ Supporting Information

^1H and ^{13}C NMR spectra and HPLC chromatograms for all compounds. This material is available free of charge via the Internet at <http://pubs.acs.org/>.

■ AUTHOR INFORMATION

Corresponding Author

*E-mail: radovan.sebesta@fns.uniba.sk.

■ ACKNOWLEDGMENTS

Financial support from the Slovak Grant Agency VEGA, Grant Nos. VEGA 1/0265/09 and VEGA 1/0546/10, and the Slovak Research and Development Agency, Grant No. VVCE 0070/07, are gratefully acknowledged. This publication is the result of the project implementation 26240120025 supported by the Research & Development Operational Programme funded by the Research & Development Operational Programme funded by the European Regional Development Fund. NMR measurements were provided by Dr. Branislav Horváth and supported by The Slovak State Programme project no. 2003SP200280203.

■ REFERENCES

- Wender, P. A.; Verma, V. A.; Paxton, T. J.; Pillow, T. H. *Acc. Chem. Res.* **2007**, *41*, 40.
- Harutyunyan, S. R.; den Hartog, T.; Geurts, K.; Minnaard, A. J.; Feringa, B. L. *Chem. Rev.* **2008**, *108*, 2824.
- Lopez, F.; Minnaard, A. J.; Feringa, B. L. *Acc. Chem. Res.* **2007**, *40*, 179.
- Alexakis, A.; Bäckvall, J. E.; Krause, N.; Pàmies, O.; Diéguez, M. *Chem. Rev.* **2008**, *108*, 2796.
- Wang, S.-Y.; Loh, T.-P. *Chem. Commun.* **2010**, *46*, 8694.
- Christoffers, J.; Koripelly, G.; Rosiak, A.; Rössle, M. *Synthesis* **2007**, *2007*, 1279.
- Gutnov, A. *Eur. J. Org. Chem.* **2008**, 4547.
- Hayashi, T.; Yamasaki, K. *Chem. Rev.* **2003**, *103*, 2829.
- Edwards, H. J.; Hargrave, J. D.; Penrose, S. D.; Frost, C. G. *Chem. Soc. Rev.* **2010**, *39*, 2093.
- Hayashi, T. *Bull. Chem. Soc. Jpn.* **2004**, *77*, 13.
- Guo, H.-C.; Ma, J.-A. *Angew. Chem., Int. Ed.* **2006**, *45*, 354.
- Jerphagnon, T.; Pizzuti, M. G.; Minnaard, A. J.; Feringa, B. L. *Chem. Soc. Rev.* **2009**, *38*, 1039.
- Arnold, L. A.; Naasz, R.; Minnaard, A. J.; Feringa, B. L. *J. Am. Chem. Soc.* **2001**, *123*, 5841.
- Arnold, L. A.; Naasz, R.; Minnaard, A. J.; Feringa, B. L. *J. Org. Chem.* **2002**, *67*, 7244.
- Brown, M. K.; Degrado, S. J.; Hoveyda, A. H. *Angew. Chem., Int. Ed.* **2005**, *44*, 5306.
- Howell, G. P.; Fletcher, S. P.; Geurts, K.; ter Horst, B.; Feringa, B. L. *J. Am. Chem. Soc.* **2006**, *128*, 14977.
- Yoshida, K.; Ogasawara, M.; Hayashi, T. *J. Am. Chem. Soc.* **2002**, *124*, 10984.
- Degradado, S. J.; Mizutani, H.; Hoveyda, A. H. *J. Am. Chem. Soc.* **2001**, *123*, 755.
- Mizutani, H.; Degrado, S. J.; Hoveyda, A. H. *J. Am. Chem. Soc.* **2002**, *124*, 779.

- Dijk, E. W.; Panella, L.; Pinho, P.; Naasz, R.; Meetsma, A.; Minnaard, A. J.; Feringa, B. L. *Tetrahedron* **2004**, *60*, 9687.
- Naasz, R.; Arnold, L. A.; Minnaard, A. J.; Feringa, B. L. *Chem. Commun.* **2001**, 735.
- Rathgeb, X.; March, S.; Alexakis, A. *J. Org. Chem.* **2006**, *71*, 5737.
- Šebesta, R.; Pizzuti, M. G.; Minnaard, A. J.; Feringa, B. L. *Adv. Synth. Catal.* **2007**, *349*, 1931.
- Xu, Y.-J.; Liu, Q.-Z.; Dong, L. *Synlett* **2007**, 273.
- Welker, M.; Woodward, S.; Alexakis, A. *Org. Lett.* **2010**, *12*, 576.
- Suárez, R. M.; Peña, D.; Minnaard, A. J.; Feringa, B. L. *Org. Biomol. Chem.* **2005**, *3*, 729.
- den Hartog, T.; Rudolph, A.; Maciá, B.; Minnaard, A. J.; Feringa, B. L. *J. Am. Chem. Soc.* **2010**, *132*, 14349.
- Li, K.; Alexakis, A. *Tetrahedron Lett.* **2005**, *46*, 8019.
- Li, K.; Alexakis, A. *Chem.—Eur. J.* **2007**, *13*, 3765.
- Agapiou, K.; Cauble, D. F.; Krische, M. J. *J. Am. Chem. Soc.* **2004**, *126*, 4528.
- Guo, S.; Xie, Y.; Hu, X.; Xia, C.; Huang, H. *Angew. Chem., Int. Ed.* **2010**, *49*, 2728.
- Gonzalez-Gomez, J. C.; Foubelo, F.; Yus, M. *J. Org. Chem.* **2009**, *74*, 2547.
- González-Gómez, J. C.; Foubelo, F.; Yus, M. *Tetrahedron Lett.* **2008**, *49*, 2343.
- Teichert, J. F.; Feringa, B. L. *Chem. Commun.* **2011**, *47*, 2679.
- Kehrli, S.; Martin, D.; Rix, D.; Mauduit, M.; Alexakis, A. *Chem.—Eur. J.* **2010**, *16*, 9890.
- Šebesta, R.; Bilčík, F.; Fodran, P. *Eur. J. Org. Chem.* **2010**, 5666.
- Galeštoková, Z.; Šebesta, R. *Eur. J. Org. Chem.* **2011**, 7092.
- Evans, D. A.; Urpi, F.; Somers, T. C.; Clark, J. S.; Bilodeau, M. T. *J. Am. Chem. Soc.* **1990**, *112*, 8215.
- Hintermann, T.; Seebach, D. *Helv. Chim. Acta* **1998**, *81*, 2093.
- Seebach, D.; Schaeffer, L.; Gessier, F.; Bindschädler, P.; Jäger, C.; Josien, D.; Kopp, S.; Lelais, G.; Mahajan, Y. R.; Micuch, P.; Sebesta, R.; Schweizer, B. W. *Helv. Chim. Acta* **2003**, *86*, 1852.
- Feringa, B. L.; Badorrey, R.; Pena, D.; Harutyunyan, S. R.; Minnaard, A. J. *Proc. Nat. Acad. Sci. U.S.A.* **2004**, *101*, 5834.
- Harutyunyan, S. R.; Lopez, F.; Browne, W. R.; Correa, A.; Pena, D.; Badorrey, R.; Meetsma, A.; Minnaard, A. J.; Feringa, B. L. *J. Am. Chem. Soc.* **2006**, *128*, 9103.
- Hawner, C.; Alexakis, A. *Chem. Commun.* **2010**, *46*, 7295.
- Tissot, M.; Pérez Hernández, A.; Müller, D.; Mauduit, M.; Alexakis, A. *Org. Lett.* **2011**, *13*, 1524.
- den Hartog, T.; Harutyunyan, S. R.; Font, D.; Minnaard, A. J.; Feringa, B. L. *Angew. Chem., Int. Ed.* **2008**, *47*, 398.
- Lopez, F.; Harutyunyan, S. R.; Minnaard, A. J.; Feringa, B. L. *J. Am. Chem. Soc.* **2004**, *126*, 12784.